AZUSA, Calif.--(BUSINESS WIRE)--Viral Genetics, Inc. (Other OTC:VRAL), a biotechnology company that discovers and develops immune-based therapies, announced today it has completed an initial study that aims to unlock the mysteries behind Lyme Disease, which could also potentially offer answers to other immune-based diseases including HIV/AIDS. In addition, a $25,000 gift has been awarded from an undisclosed source to further explore this new model in Lyme Disease through follow-on studies which researchers, including lead investigator Professor M. Karen Newell, PhD, Professor at the University of Colorado at Colorado Springs, hope will serve to reconcile the long-standing and controversial debate in the medical community over treatment methods for Lyme Disease.
